Buscar resultados de ensayos clínicos
Idiopathic Pulmonary Fibrosis - 43 Studies Found
Estado | Estudiar |
Completed |
Nombre del estudio: Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis Condición: Idiopathic Pulmonary Fibrosis Fecha: 2010-09-30 Intervenciones:
|
Recruiting |
Nombre del estudio: Validation of the Risk Stratification Score in Idiopathic Pulmonary Fibrosis Condición: Idiopathic Pulmonary Fibrosis Fecha: 2015-12-13 |
Completed |
Nombre del estudio: Safety and Tolerability Study of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis Condición: Idiopathic Pulmonary Fibrosis Fecha: 2003-12-18 Intervenciones: Drug: FG-3019 |
Completed |
Nombre del estudio: Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis Condición: Idiopathic Pulmonary Fibrosis Fecha: 2003-10-23 Intervenciones:
|
Recruiting |
Nombre del estudio: Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis Condición: Idiopathic Pulmonary Fibrosis Fecha: 2016-04-01 Intervenciones:
|
RECRUITING |
Nombre del estudio: The Effect of N115 on Coughing in IPF Patients Condición: Idiopathic Pulmonary Fibrosis Fecha: 2024-05-19 Intervenciones: The product is a 20 mM (0.2%, 2.2 mg/mL) sodium pyruvate nasal spray in 0.9% sodium chloride with 0.02% benzalkonium chloride preservative, pH 7. |
RECRUITING |
Nombre del estudio: A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis Condición: Idiopathic Pulmonary Fibrosis Fecha: 2024-05-19 Intervenciones: Specified dose on specified days |
RECRUITING |
Nombre del estudio: Atezolizumab for Idiopathic Pulmonary Fibrosis Condición: Idiopathic Pulmonary Fibrosis Fecha: 2024-05-19 Intervenciones: Atezolizumab 1200 mg administered via intravenous infusion every 3 weeks |
RECRUITING |
Nombre del estudio: Safety and Efficacy of Venetoclax in Idiopathic Pulmonary Fibrosis Condición: Idiopathic Pulmonary Fibrosis Fecha: 2024-05-19 Intervenciones: 100 mg daily by mouth for 3 weeks This drug inhibits a protein (Bcl-2) that protects cells from undergoing programmed cell death. |
RECRUITING |
Nombre del estudio: Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis Condición: Idiopathic Pulmonary Fibrosis (IPF) Fecha: 2024-05-19 Intervenciones: Pharmaceutical formulation: CapsulesMode of Administration: Oral |